School of Medicine
Showing 61-70 of 80 Results
-
Anne Liu
Clinical Associate Professor, Pediatrics - Immunology and Allergy
Clinical Associate Professor (By courtesy), Medicine - Pulmonary, Allergy & Critical Care MedicineBioDr. Liu is a board-certified, fellowship-trained specialist in allergy/immunology and infectious disease. She is also a clinical associate professor in the Department of Medicine, Division of Infectious Diseases and the Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology at Stanford University School of Medicine.
Dr. Liu treats infections in patients with compromised immune systems, whether due to a primary immune deficiency or a condition like cancer or organ transplant. She helps patients to develop tolerance to medications they are allergic to so that they can receive the best, and sometimes the only, treatments available to them. She also treats allergies to antibiotics, aspirin, NSAIDs, chemotherapy, and more. She sees patients both long term and for urgent referrals, such as in cases of perioperative anaphylaxis. Dr. Liu also helps pediatric patients manage drug and food allergies.
One of Dr. Liu’s areas of focus is helping patients with allergies to antibiotics determine when they have lost an allergy, what antibiotics they can tolerate, and when to induce tolerance to an antibiotic. This not only can benefit the patient, but also have a positive public health impact, as labeling patients with a penicillin allergy may negatively affect their care and increase use
of broad-spectrum antibiotics.
She collaborates closely with colleagues from other disciplines, including pulmonology, otolaryngology, oncology, cardiology, dermatology, anesthesiology, and surgery. Her key objective in working with referring physicians is to help them safely deliver the best care for their patients.
For patients and families, Dr. Liu strives to help them navigate their care journey with as much ease and dignity as possible during what may be the most challenging time of their life. Her goal is to offer patients options, even when it may appear that they have no options left.
Dr. Liu’s research interests include optimizing care of patients with antibiotic allergies, including through use of decision support tools.
Dr. Liu has authored articles in the New England Journal of Medicine, Journal of Immunology, Journal of Allergy and Clinical Immunology in Practice, Clinical and Experimental Allergy, Mucosal Immunology, Diagnostic Microbiology and Infectious Disease, Science, and other publications. Dr. Liu authored the book chapter “Hypersensitivity Reactions to Monoclonal Antibodies” in Drug Allergy Testing.
Dr. Liu is certified in infectious disease by the American Board of Internal Medicine and in allergy and immunology by the American Board of Allergy and Immunology. She is also a member of the American College of Physicians, Infectious Diseases Society of America, and American Academy of Allergy, Asthma, and Immunology.
She has given presentations on antibiotic allergies, drug desensitization, and aspirin-exacerbated respiratory disease, among other topics. Dr. Liu’s honors include recognition from the American Academy of Asthma, Allergy, and Immunology, the American Medical Women’s Association, and the National Institutes of Health. -
Christine Kee Liu
Assistant Professor of Medicine (Primary Care and Population Health)
BioDr. Liu and her research program are dedicated to improving the lives of older adults with kidney disease. Currently her research focuses on mobility, which is the ability to move safely and reliably from one place to another. In older adults, poor mobility strongly predicts future disability and death. Retaining mobility has been cited by older adults as fundamental to quality to life; yet many older persons with kidney disease, especially those with late stage chronic kidney disease or outright kidney failure, have trouble just walking across the room or transferring to a chair. Dually trained in geriatric medicine and epidemiology, Dr. Liu also has significant expertise in older adult clinical trials, including safety trials of novel agents as well as intervention studies to reduce infections in older populations.
-
Nathan Lo
Assistant Professor of Medicine (Infectious Diseases)
Current Research and Scholarly InterestsOur research laboratory is interested in studying the transmission of infectious diseases and impact of public health interventions with an ultimate goal of informing public health policy. We study a diverse set of pathogens including vaccine-preventable infections (including COVID-19) and neglected tropical diseases. Our group applies diverse computational methodologies, including tools of epidemiology, modeling, pathogen genomics, and policy analysis.
A large emphasis of our work is translating scientific evidence into public health policy. Our track record includes multiple studies that have changed policy in the fields of neglected tropical diseases and COVID-19. We work closely with policy organizations like the World Health Organization and the California Department of Public Health.
Our current research focuses on the following areas:
(1) Vaccine-preventable infectious diseases (including COVID-19) in the United States, with a focus on studying vaccines and transmission dynamics
(2) Public health strategies for control and elimination of globally important neglected infectious diseases, such as helminths infections (schistosomiasis, strongyloidiasis) and typhoid fever
Hiring
We are seeking to fill multiple research positions at all levels. Candidates interested in working on computational public health research related to infectious diseases with a strong quantitative background are highly encouraged to apply. If you an interested, please submit a cover letter, CV, and names of two references to Nathan.Lo@stanford.edu. -
Karl Lorenz
Professor of Medicine (Primary Care and Population Health)
BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.
-
Kate Lorig
Professor (Research) of Medicine (Immunology and Rheumatology), Emerita
Current Research and Scholarly InterestsCommunity based psycoeducational intervention studies of disease self management for people with chronic diseases. arthritis, lung diseases, heart disease AIDs, low back pain and diabetes. Programs and studies in Spanish and English. Interventions are in small groups, mailed or on the Internet.
-
Anson Lowe
Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.
